News – Page 1115 – Endpoints News

With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M

8 years ago

Tiny Innate reports a PhIIb disaster, battering shares — and a NY congressman

8 years ago

Pfizer preps new hires as it begins building a $200M R&D campus

8 years ago

Mitoconix lands $20M to develop neurodegenerative platform out of Stanford; RaNA gets a new name following mRNA deal ...

8 years ago

Teva and Xenon rack up another setback as PhIIb study fails on every endpoint

8 years ago

In a stunner, Merck lands positive PhIII for its CETP outcast anacetrapib

8 years ago

Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field

8 years ago

Scoop: Martin Shkreli bats back a coup at Turing, new board considers a sale of assets

8 years ago

Alnylam makes a bull case for PhIII-ready porphyria drug, but shares sink anyway

8 years ago

Langer-inspired Kala files for an $86M IPO; J&J backs Provention Bio

8 years ago

After months of taunts and tantrums, Martin Shkreli's fraud trial gets underway

8 years ago

Neothetics ponders the future after sole therapy proves an ugly flop in PhII, eviscerating shares

8 years ago

Matinas Bio shares are crushed on disappointing PhII antifungal data

8 years ago

Seattle Genetics gets a PhIII win for Adcetris, but shares slide as frets linger

8 years ago

Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger

8 years ago

FDA OKs Portola’s anticoagulant betrixaban for preventing blood clots

8 years ago

OvaScience and Active Biotech name new CEOs, Valeant adds John Paulson to the board

8 years ago

Merck KGaA gets a thumbs up for once-dead MS drug; Aveo shares soar as tivo makes a comeback

8 years ago

PhIII-focused Cara sees shares spike on its new ‘breakthrough’ status at the FDA

8 years ago

CRISPR crew’s lab test spotlights lead program in sickle cell disease, beta-thalassemia

8 years ago

Bluebird bio steps up with a promising snapshot of its gene therapy upgrade

8 years ago

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

8 years ago

The closest thing to a shoo-in Pfizer has ever handed to the FDA just got rejected

8 years ago

The Endpoints 100 CEO Survey: Execs offer a big thumbs up for Gottlieb and some suggestions for making the FDA a ...

8 years ago

First page Previous page 1112 1113 111411151116 1117 1118 Next page Last page